Abstract
APOE ε4 allele is a major risk factor in Late-Onset Alzheimer’s Disease (AD). Distinct phenotypes that depend on the APOE ε4 status have been demonstrated. The genetic etiology of APOE ε4 non-carriers is still elusive. Thus we investigated the genetic components of AD that is independent of APOE ε4 by combining genome association analysis with quantitative trait analyses in non-Hispanic Caucasian participants in the Alzheimer’ s Disease Neuroimaging Initiative (ADNI) cohort. Five top susceptible single nucleotide polymorphisms (SNPs) in three loci in ZNF827, KDM2B and NANP were initially identified in APOE ε4 non-carriers and four of these SNPs were confirmed in mild cognitive impairment. These SNPs and one nominally significant SNP are located in three haplotype blocks. Quantitative trait analyses of these haplotype blocks demonstrated that the haplotype block in ZNF827 was associated with CSF Aβ42 level, and the haplotype block in KDM2B with CSF p-tau181p and p-tau181p/Aβ42 ratio. The haplotype block between NANP and NINL was associated with brain atrophy. Moreover, these SNPs took additive effects on AD incidence and demonstrated the interaction with APOE ε4 status. Therefore, we conclude that these novel loci are associated with AD in APOE ε4 non-carriers. This study indicates the distinct genetic risk genes for AD non-carrying APOE ε4 and provides new insight into the molecular mechanisms of AD.
Keywords: Alzheimer’ s disease, apolipoprotein E ε 4, brain atrophy, diagnostic biomarker, haplotype, single nucleotide polymorphism.
Current Alzheimer Research
Title:Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE ε 4 Non-Carriers of Alzheimer’s Disease
Volume: 12 Issue: 3
Author(s): Shan Jiang, Wanling Yang, Yu Qiu, Hong-Zhuan Chen and for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Affiliation:
Keywords: Alzheimer’ s disease, apolipoprotein E ε 4, brain atrophy, diagnostic biomarker, haplotype, single nucleotide polymorphism.
Abstract: APOE ε4 allele is a major risk factor in Late-Onset Alzheimer’s Disease (AD). Distinct phenotypes that depend on the APOE ε4 status have been demonstrated. The genetic etiology of APOE ε4 non-carriers is still elusive. Thus we investigated the genetic components of AD that is independent of APOE ε4 by combining genome association analysis with quantitative trait analyses in non-Hispanic Caucasian participants in the Alzheimer’ s Disease Neuroimaging Initiative (ADNI) cohort. Five top susceptible single nucleotide polymorphisms (SNPs) in three loci in ZNF827, KDM2B and NANP were initially identified in APOE ε4 non-carriers and four of these SNPs were confirmed in mild cognitive impairment. These SNPs and one nominally significant SNP are located in three haplotype blocks. Quantitative trait analyses of these haplotype blocks demonstrated that the haplotype block in ZNF827 was associated with CSF Aβ42 level, and the haplotype block in KDM2B with CSF p-tau181p and p-tau181p/Aβ42 ratio. The haplotype block between NANP and NINL was associated with brain atrophy. Moreover, these SNPs took additive effects on AD incidence and demonstrated the interaction with APOE ε4 status. Therefore, we conclude that these novel loci are associated with AD in APOE ε4 non-carriers. This study indicates the distinct genetic risk genes for AD non-carrying APOE ε4 and provides new insight into the molecular mechanisms of AD.
Export Options
About this article
Cite this article as:
Jiang Shan, Yang Wanling, Qiu Yu, Chen Hong-Zhuan and for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE ε 4 Non-Carriers of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302160145
DOI https://dx.doi.org/10.2174/1567205012666150302160145 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond
Current Pharmaceutical Design Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Editorial (Hot Topic : Computational Prediction of Drug-Target Interactions in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Developments in HIV Neuropathogenesis
Current Pharmaceutical Design Diabetic Cognitive Dysfunction: From Bench to Clinic
Current Medicinal Chemistry Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science The Six Item Cognitive Impairment Test (6-CIT) as a Screening Test for Dementia: Comparison with Mini-Mental State Examination (MMSE)
Current Aging Science Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Pharmacogenetics and Pharmagenomics, Trends in Normal and Pathological Aging Studies: Focus on p53
Current Pharmaceutical Design Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics
Current Alzheimer Research Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors
Current Pharmaceutical Design Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Ameliorative Effects of Baicalein on an Amyloid-β Induced Alzheimer's Disease Rat Model: A Proteomics Study
Current Alzheimer Research Formulation and In Vitro Evaluation of Gelatin Nanospheres for the Oral Delivery of Selegiline
Current Nanoscience